This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status was investigated.
INTRODUCTION
The epidermal growth factor receptor (EGFR) is a clinically validated anticancer molecular target that is expressed in the majority of colorectal tumors. [1] [2] [3] [4] [5] Cetuximab (Erbitux, developed by Merck KGaA [Darmstadt, Germany] , under license from Imclone New York, NY]) is an immunoglobulin G1 monoclonal antibody that specifically targets EGFR with high affinity, competitively inhibiting endogenous ligand binding and liganddependent downstream signaling. 6, 7 Binding to the tumor cell also initiates antibody-dependent cell-mediated cytotoxicity. [8] [9] [10] Randomized phase II and III metastatic colorectal cancer (mCRC) studies have demonstrated the efficacy and tolerability of cetuximab, as monotherapy 2, 11 or in combination with irinotecan, 2, 12 after the failure of previous chemotherapy regimens including irinotecan and/or oxaliplatin. Furthermore, in the first-line setting, building on promising phase II data, 13 the phase III Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) study has shown that the addition of cetuximab to infusional fluorouracil (FU)/leucovorin (LV)/irinotecan (FOLFIRI) significantly improves the progression-free survival (PFS) time, response rate, and R0 resection rate in mCRC patients, compared with FOLFIRI alone. 14 Phase II studies examining the activity and tolerability of cetuximab combined with oxaliplatin and FU/LV (FOLFOX-4) have provided encouraging results. 15, 16 To further evaluate this combination, the Oxaliplatin and Cetuximab in First-Line Treatment of mCRC (OPUS) study compared the efficacy and safety of cetuximab plus FOLFOX-4 with FOLFOX-4 alone as first-line therapy for mCRC.
The definition of relevant molecular characteristics of an individual tumor (biomarker evaluation) will increasingly enable the selection of patients most likely to benefit from particular treatments. 17 A recent subgroup analysis of a randomized phase III study of the immunoglobulin G2 EGFR-targeting monoclonal antibody panitumumab in patients with chemotherapy-refractory mCRC suggested a lack of clinical activity in patients whose tumors had activating mutations at codon 12 or 13 of the KRAS gene. 18 Small retrospective studies in chemotherapy-refractory patients have also suggested that clinical responses to cetuximab are confined to those mCRC patients (approximately 55% to 70%) whose tumors are wild type for KRAS. [19] [20] [21] [22] This assertion has recently been confirmed in subgroup analyses of the randomized phase III CRYSTAL and CO.17 studies. 23,24 A subgroup analysis of the OPUS study therefore investigated whether tumor KRAS mutation status was predictive of a clinical response to cetuximab plus FOLFOX-4.
PATIENTS AND METHODS

Patient Eligibility
Patients were eligible for inclusion if they were Ն 18 years old; had a histologically confirmed, first-occurrence of a nonresectable, EGFRexpressing mCRC with at least one radiologically measurable lesion; a life expectancy of Ն 12 weeks; an Eastern Cooperative Oncology Group Performance Status (ECOG PS) Յ 2; and adequate hepatic, renal, and bone marrow function. Patients were ineligible if they were pregnant, had a history of previous exposure to EGFR-targeted therapy or previous chemotherapy (except adjuvant treatment) for mCRC, or had uncontrolled severe organ or metabolic dysfunction. The study was approved by relevant ethics committees and was conducted in accordance with the Declaration of Helsinki. All patients provided written, informed consent.
Study Design
This was an open-label, randomized, multicenter phase II study comparing the efficacy and safety of cetuximab combined with FOLFOX-4 versus FOLFOX-4 alone in the first-line treatment of EGFR-expressing mCRC. EGFR expression was determined using a DakoCytomation pharmDx immunohistochemistry kit (Dako, Glostrup, Denmark), with one tumor cell staining to any intensity being the minimum criterion required to confirm expression. Randomization (1:1) was carried out using a stratified permutedblock procedure, with ECOG PS (0 and 1 v 2) as a stratification factor.
On day 1 of a 14-day treatment cycle, patients received cetuximab (initial dose 400 mg/m 2 infused during 2 hours, and 250 mg/m 2 weekly during 1 hour thereafter) followed after 1 hour by FOLFOX-4 (oxaliplatin 85 mg/m 2 on day 1, infused during 2 hours; LV 200 mg/m 2 , infused during 2 hours, followed by FU as a 400 mg/m 2 intravenous bolus then a 600 mg/m 2 infusion during 22 hours on days 1 and 2) or FOLFOX-4 alone, until the occurrence of progressive disease (PD) or unacceptable toxicity. In the case of unacceptable toxicity or intolerance to FU/LV, oxaliplatin, or cetuximab, the agent responsible could be stopped and the patient could continue with the other study medication(s). Radiologic assessment of response was carried out every 8 weeks until PD or withdrawal for any reason.
The primary objective was to assess whether the best confirmed overall response rate of cetuximab plus FOLFOX-4 was superior to that of FOLFOX-4 alone. Tumor response including disease progression was assessed by an independent review committee according to modified WHO criteria. The independent review committee conducted a blinded review of images and clinical data using a common set of prespecified criteria. The data cutoff for the primary analysis of response was chosen to be 20 weeks after the last randomly assigned patient started study treatment (August 4, 2006) so that all patients could have at least two 8-week evaluations. Secondary objectives included treatment comparisons of the rate of curative metastatic surgery, duration of response, disease control rate, PFS time, OS time, and safety, all of which were based on data from a longer follow-up time (March 1, 2007) . A retrospective subgroup analysis investigated associations between PFS and response rate and the KRAS mutation status of tumors.
Statistical Methods and Considerations
The primary efficacy analysis was performed on the intention-totreat (ITT) population, defined as all randomly assigned patients who received at least one dose of study treatment. Assuming a difference in the rate of best confirmed response of at least 20% between the two treatments (ie, approximately 70% with cetuximab plus FOLFOX-4 and 50% with FOLFOX-4 alone for the stratum with ECOG PS 0 to 1, and 66% and 45%, respectively, for the ECOG PS 2 stratum), the Cochran-Mantel-Haenszel (CMH) 25,26 odds ratio (OR) over the strata was expected to be 2.33. A sample size of approximately 146 patients per group was therefore calculated as necessary to detect an odds ratio of 2.33 at level ␣ ϭ .05, with a power of 90%. With the exception of the test of the null hypothesis of OR ϭ 1 over the entire sample population, all further efficacy analyses were exploratory and P values were not adjusted for the multiplicity of statistical tests. Time-to-event data were analyzed using the Kaplan-Meier method. 27 All analyses were repeated by KRAS mutation status in those ITT patients whose tumors were available and provided an assessable DNA sample (KRAS population).
KRAS Mutation Detection
Tumor DNA was extracted from formaldehyde-fixed paraffin-embedded tissues, and screened for the presence of KRAS codon 12 and 13 mutations using a polymerase chain reaction (PCR) clamping and melting curve technique adapted from Chen et al 28 (full methods information is listed in the Appendix, online only). Briefly, a one-step Lightcycler PCR reaction (Light-Mix, k-ras Gly12; TIB MOLBIOL, Berlin, Germany) incorporated a codon 12 to 14 spanning locked nucleic acid oligomer to suppress amplification of the wild-type sequence. 29 Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations.
Safety Analysis
The safety population comprised all patients who received at least one dose of study treatment. All adverse events (AEs) reported with onset on or after the first day of study medication and captured up to 6 weeks after the end of the last administration of study treatment were coded using the Medical Dictionary for Regulatory Activities version 8.1 and summarized by worst severity per patient according to the National Cancer Institute Common Toxicity Criteria version 2.0.
RESULTS
Patient Demographics
Three hundred forty-four patients were randomly assigned (three of them in error). Of the eligible patients, 337 received study treatment at 79 centers. Study accrual lasted from July 2005 until March 2006, with 169 patients receiving cetuximab plus FOLFOX-4 and 168 patients receiving FOLFOX-4 alone (Fig 1) . Baseline demographic and disease characteristics were generally well balanced between the treatment groups (Table 1) . DNA suitable for KRAS mutation analysis was extracted from the tumor samples of 233 patients, 113 and 120 of whom had received cetuximab plus FOLOFOX-4 and FOLFOX-4 alone, respectively. These patients comprised the KRAS population. In general, the population with tissue available for KRAS analysis (n ϭ 233) was considered to be representative of the overall ITT population (n ϭ 337) in relation to demographic parameters (Table 1) .
Treatment Compliance
The median duration of cetuximab treatment was 24 weeks, with 84% of patients having a relative dose-intensity (RDI) of Ն 80%. Similar numbers of patients in both arms had RDIs of Ն 80% for oxaliplatin (75% and 80% of patients receiving cetuximab plus 2  1  3  3  2  2  1  1  2  3  2  4  0  Partial response  59  35  75  44  47  39  52  46  26  36  35  57  21  45  17  33  Stable disease  76  45  67  40  47  39  46  41  30  41  19  31  17  36  27  52  Progressive disease  21  13  18  11  17  14  10  9  12  16  3  5  5  11  7  13  Not assessable  11  7  7  4  6  5  3  3  4  5  2  3  2  4  1  2  Best overall FOLFOX-4 and FOLFOX-4, respectively) and FU (67% and 70% of patients, respectively). Reductions and delays in cetuximab dosing were primarily because of skin reactions, and delays in chemotherapy dosing were because of hematologic, GI, or neurologic reactions. In the KRAS population, comparable levels of exposure were reached; 86% of patients who received cetuximab had a RDI Ն 80%. RDIs of Ն 80% were also reported for 73% and 81% of patients receiving oxaliplatin and for 65% and 72% of patients receiving FU in the cetuximab plus FOLFOX-4 and FOLFOX-4 arms, respectively.
Efficacy
Efficacy data are summarized in Table 2 . The best confirmed overall response rate in the cetuximab plus FOLFOX-4 group was 46%, and in the FOLFOX-4 -alone group, this value was 36%. The comparison between the two treatment groups resulted in a common ECOG PS-adjusted OR of 1.52 (95% CI, 0.98 to 2.36), indicating an increase in the chance of a response in the cetuximab plus FOLFOX-4 arm by 52%. This increase was not statistically significant at the 5% level (ECOG PS-adjusted CMH test, P ϭ .064). A slightly greater treatment effect was observed in the group of participants (n ϭ 153 v 152) with ECOG PS 0 to 1 (OR ϭ 1.65; 95% CI, 1.04 to 2.60; CMH test, P ϭ .032). Regarding the secondary efficacy end points, although a marked benefit in relation to PFS time was not detected ( Table 2 ; Fig 2A) , the addition of cetuximab to FOLFOX-4 was associated with an approximate doubling of the R0 resection rate from 2.4% (four of 168 patients) for FOLFOX-4 alone to 4.7% (eight of 169 patients) for cetuximab plus FOLFOX-4. The median duration of response was also longer in the cetuximab group (9.0 v 5.7 months).
KRAS mutations in codons 12/13 (hereinafter called KRAS mutations) were detected in the tumor tissue of 99 of 233 (42%) patients, 52 of whom received cetuximab plus FOLFOX-4 and 47 of whom received FOLFOX-4 alone ( Table 2) . No mutations were detected in the tumors of 134 patients (58%; hereinafter called KRAS wild-type tumors), 61 of whom received cetuximab plus FOLFOX-4 and 73 of whom received FOLFOX-4 alone. In patients whose tumors were scored as KRAS wild type, the addition of cetuximab to FOLFOX-4 was associated with a 2.54-fold increased chance for response compared with FOLFOX-4 alone (61% v 37%; OR ϭ 2.54; 95% CI, 1.24 to 5.23; ECOG PS-adjusted CMH test, P ϭ .011). Conversely, for patients with tumor KRAS mutations, the response rate for cetuximab plus FOLFOX-4 was lower, compared with FOLFOX-4 alone (33% v 49%; OR ϭ 0.51; 95% CI, 0.22 to 1.15; ECOG PS-adjusted CMH test, P ϭ .106). The R0 resection rate was more than doubled in patients with KRAS wild-type tumors who received cetuximab plus FOLFOX-4 (six of 61 patients; 9.8%) compared with those who received FOLFOX-4 alone (three of 73 patients; 4.1%). In contrast, in patients whose tumors carried KRAS mutations, R0 resection rates were similar in both treatment arms (one in 52 and one in 47 patients, respectively; 1.9% and 2.1%). However, due to the small patient numbers, these data have to be interpreted with caution.
The risk of disease progression (Figs 2A and 2B) was similar for both the ITT (cetuximab plus FOLFOX-4 v FOLFOX-4 alone; hazard ratio [HR] ϭ 0.93; log-rank test, P ϭ .6170) and the KRAS population (HR ϭ 0.93; log-rank test, P ϭ .6609), adding additional evidence consistent with the representability of the KRAS population. A marked risk reduction for progression was evident between the study arms when comparing patients according to whether KRAS mutations were detected in their tumor DNA. Specifically, as summarized in Table 2 and Figure 3 , the addition of cetuximab to FOLFOX-4 was associated with a 43% reduction in the risk of progression in patients with KRAS wild-type tumors (Fig 3C; HR ϭ 0.57; log-rank test, P ϭ .0163). In those patients receiving cetuximab plus FOLFOX-4, the risk of disease progression was lower for those whose tumors were wild type for KRAS, compared with those whose tumors carried mutations ( Fig 3A; HR ϭ 0.45; log-rank test, P ϭ .0009). However, in patients whose tumors carried mutations of KRAS, the risk of disease progression was found to be lower for those receiving FOLFOX-4 alone compared with those receiving cetuximab plus FOLFOX-4 ( Fig 3D; A HR ϭ 1.83; log-rank test, P ϭ .0192). For patients receiving FOLFOX-4 alone, a trend for reduced risk of disease progression associated with tumor KRAS mutation was also apparent ( Fig 3B; HR ϭ 1.40; log-rank test, P ϭ .1655).
Safety
The most common AEs at any grade were skin and subcutaneous tissue disorders (90%) and GI disorders (78%) in the cetuximab plus FOLFOX-4 group, and GI disorders (73%) and myelotoxicity (71%) in the FOLFOX-4 -alone group. The most common grade 3/4 AEs were neutropenia (30% v 34%), rash (11% v 0.6%), and diarrhea (8% v 7%) respectively, for the cetuximab plus FOLFOX-4 versus the FOLFOX-4 -alone group (Table 3 ).
In the cetuximab plus FOLFOX-4 group, cetuximab was discontinued in 39 patients (23%), chemotherapy was discontinued in 51 patients (30%), and both were discontinued in 16 patients (9%) due to AEs. Chemotherapy was discontinued in 42 patients (25%) in the FOLFOX-4 -alone group due to AEs. The most com-mon reasons for cetuximab discontinuation were hypersensitivity reactions (4%) and rash (4%), in accordance with guidelines prespecified in the protocol, and for chemotherapy discontinuation in the cetuximab plus FOLFOX-4 group, neutropenia (4%) and neuropathy (3%). In the FOLFOX-4 -alone group, peripheral sensory neuropathy (5%), neuropathy and paresthesia (4%), and neutropenia (2%) were the most common reasons for treatment discontinuation.
At the time of analysis, 111 patients had died; 60 patients (35%) in the cetuximab plus FOLFOX-4 group and 51 patients (30%) in the FOLFOX-4 -alone group, mainly due to PD (94 patients). No deaths were related to cetuximab.
DISCUSSION
The rationale for testing cetuximab in combination with FOLFOX-4 rested on preclinical data suggesting that cetuximab improved the antitumor activity of oxaliplatin and also on promising clinical phase II study data. 16, 30 The confirmed best overall response rate for the ITT population, as assessed by blinded independent review, was increased by 10 percentage points by the addition of cetuximab to FOLFOX-4, compared with FOLFOX-4 alone (46% v 36%). Although this difference showed a clinically relevant and strong trend, a statistically significant increase in the odds for a response with the addition of cetuximab to FOLFOX-4 could not be established (P ϭ .064).
Although there was no apparent difference in PFS time between the ITT population treatment arms, when retrospective efficacy analyses were carried out in the KRAS population according to KRAS mutation status, striking differences were apparent in relation to tumor response and the risk of disease progression. Patients whose tumors were wild type for KRAS had a clinically relevant increase in the chance of response (61% v 37%; OR ϭ 2.54; P ϭ .011) and decrease in the risk of disease progression (HR ϭ 0.57; P ϭ .016) in the cetuximab plus FOLFOX-4 arm compared with those in the FOLFOX-4 -alone arm. Somewhat unexpected was the observation that patients whose tumors carried a mutation in KRAS were more likely to derive a clinical benefit if treated with FOLFOX-4 alone rather than cetuximab plus FOLFOX-4 ( Fig 3D) . Similarly, considering patients receiving FOLFOX-4 alone, there was a trend for improved progression-free survival time in patients whose tumors carried a KRAS mutation ( Fig 3B) .
It remains to be seen whether the apparently better outcome of patients whose tumors carried KRAS mutations who were treated with FOLFOX-4 alone compared with those treated with cetuximab plus FOLFOX-4 was a chance finding, or whether it might have a biologic explanation. Given that a comparable effect was not observed in equivalent patient groups in the CRYSTAL study when cetuximab was added to FOLFIRI, 23 the type of chemotherapy (platinum based compared with nonplatinum based) may be a factor in any possible interaction. It is interesting to note in this context that the subgroup of genotyped patients in the randomized phase III CAIRO2 study whose tumors had a mutation in the KRAS gene (n ϭ 196) who received capecitabine/oxaliplatin plus bevacizumab (n ϭ 103) had significantly better PFS than those who received the same regimen plus cetuximab (n ϭ 93). 31 The OPUS and CAIRO2 studies therefore raise the possibility that in relation to tumors with mutations in the KRAS gene, the addition of EGFR-targeted agents to oxaliplatin-based chemotherapy may impair the efficacy of a cytotoxic component of the combined regimen. In addition, a specific interaction between bevacizumab and cetuximab in relation to the treatment of tumors with KRAS mutations cannot be excluded. Experimental studies are therefore warranted to explore such hypothetical treatment effects in KRAS mutant mCRCs with a view to devising novel clinical strategies to allow extension of the benefit of anti-EGFR therapy to patients whose tumors have KRAS mutations.
In line with recent findings from a phase I dose-escalation study of cetuximab with FOLFIRI, 32 and the first-line data from the phase III CRYSTAL study, 23 the results of the current analysis confirm published data from previously treated mCRC, regarding restriction of the activity of cetuximab to patients whose tumors are wild type for KRAS. [19] [20] [21] [22] 24 The KRAS data also emphasize the fact that the higher clinical benefit associated with cetuximab essentially may be masked, or at the least underestimated, when considering overall populations of unselected patients in randomized studies, as illustrated by the nonsignificant results in response rate and the comparable risk of disease progression in the ITT population.
The combination of cetuximab and FOLFOX-4 was generally well tolerated, and there was no evidence to suggest that cetuximab increased the frequency or severity of the known toxicities of oxaliplatin and FU or vice versa. In addition, the incidence and severity of skin reactions, infusion-related reactions, and mucositis were consistent with the known safety profile of cetuximab.
In conclusion, this study demonstrated that to a clinically meaningful extent, the addition of cetuximab to FOLFOX-4 as first-line treatment for mCRC increased the overall response rate and reduced the risk of disease progression in patients whose tumors were wild type for KRAS, compared with FOLFOX-4 alone. These data confirm that KRAS mutation status is a powerful predictive factor in relation to the efficacy of cetuximab treatment, and are a clear demonstration of the potential and increasing importance of tumor biomarker analysis as a component of treatment selection in the clinic. 
